Published in J Am Coll Cardiol on December 03, 2003
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis (2011) 2.01
Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol (2014) 1.48
TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev (2011) 1.47
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart (2005) 1.17
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail (2009) 1.09
Methodology and applications of disease biomarker identification in human serum. Biomark Insights (2007) 0.97
Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev (2008) 0.95
The obesity paradox in men versus women with systolic heart failure. Am J Cardiol (2012) 0.95
Statin treatment for patients with heart failure. Nat Rev Cardiol (2010) 0.94
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart (2006) 0.92
Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer. Wien Klin Wochenschr (2009) 0.90
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag (2008) 0.86
Statins in the treatment of chronic heart failure: a systematic review. PLoS Med (2006) 0.85
Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz (2009) 0.85
Beyond lipid lowering: pleiotropic effects of statins in heart failure. Neth Heart J (2013) 0.82
Associations of high HDL cholesterol level with all-cause mortality in patients with heart failure complicating coronary heart disease. Medicine (Baltimore) (2016) 0.81
Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J Intern Med (2014) 0.80
Heart failure and statins--why do we need a clinical trial? Z Kardiol (2005) 0.80
Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: a retrospective analysis in a community setting. Eur J Clin Pharmacol (2015) 0.80
Inflammatory Markers-Serum Level of C-Reactive Protein, Tumor Necrotic Factor-α, and Interleukin-6 as Predictors of Outcome for Peripartum Cardiomyopathy. J Obstet Gynaecol India (2013) 0.79
Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. Vasc Health Risk Manag (2009) 0.79
Relationship between lipids levels and right ventricular volume overload in congestive heart failure. J Geriatr Cardiol (2014) 0.79
Should a statin be prescribed to every patient with heart failure? Heart Fail Rev (2007) 0.76
Different effect of hypercholesterolemia on mortality in hemodialysis patients based on coronary artery disease or myocardial infarction. Lipids Health Dis (2016) 0.75
Cholesterol and mortality in heart failure: the bad gone good? J Am Coll Cardiol (2003) 0.75
Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation. Circ Heart Fail (2016) 0.75
Cholesterol is required for maintaining T-tubule integrity and intercellular connections at intercalated discs in cardiomyocytes. J Mol Cell Cardiol (2016) 0.75
Low serum triglyceride levels as predictors of cardiac death in heart failure patients. Tex Heart Inst J (2013) 0.75
Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J (2012) 0.75
Abnormal myocardial perfusion and risk of heart failure in patients with type 2 diabetes mellitus. Exp Clin Cardiol (2013) 0.75
Effects of Statin Therapy on Clinical Outcomes of Survivors of Acute Myocardial Infarction with Severe Systolic Heart Failure. PLoS One (2015) 0.75
Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep (2017) 0.75
No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. PLoS One (2017) 0.75
Association of total cholesterol and HDL-C levels and outcome in coronary heart disease patients with heart failure. Medicine (Baltimore) (2017) 0.75
The role of statins in chronic heart failure. Kardiochir Torakochirurgia Pol (2014) 0.75
A novel prediction model for all cause emergency department visits in ischemic heart disease. J Res Med Sci (2011) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Frailty consensus: a call to action. J Am Med Dir Assoc (2013) 6.54
Cachexia: a new definition. Clin Nutr (2008) 5.49
Increased metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol (1985) (2007) 4.02
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 3.89
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation (2009) 3.05
Ethical authorship and publishing. Int J Cardiol (2008) 2.97
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. Eur Heart J (2005) 2.84
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr (2006) 2.67
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2012) 2.60
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc (2010) 2.55
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol (2005) 2.28
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol (2010) 2.25
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Pregnancy after varicocelectomy: impact of postoperative motility and DFI. Urology (2013) 2.20
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
Genome-wide prediction of G4 DNA as regulatory motifs: role in Escherichia coli global regulation. Genome Res (2006) 2.12
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 2.10
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail (2005) 2.06
Top of the charts: download versus citations in the International Journal of Cardiology. Int J Cardiol (2005) 2.06
Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle (2010) 2.04
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
Clinical relevance of oxidative stress in male factor infertility: an update. Am J Reprod Immunol (2008) 1.98
Oxidative stress & male infertility. Indian J Med Res (2009) 1.93
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Statement on authorship and publishing ethics in the International Journal of Cardiology. Int J Cardiol (2011) 1.90
An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle (2010) 1.89
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail (2009) 1.88
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J (2008) 1.85
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol (2002) 1.83
Anemia and inflammation in COPD. Chest (2005) 1.83
Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care (2007) 1.82
Contemporary (post-Wills) survey of the views of Australian medical researchers: importance of funding, infrastructure and motivators for a research career. Med J Aust (2005) 1.79
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J (2007) 1.75
A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol (2013) 1.73
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail (2009) 1.73
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation (2002) 1.70
Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J (2007) 1.69
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.68
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA (2003) 1.64
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail (2011) 1.61
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res (2007) 1.61
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol (2011) 1.59
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59
IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging (2013) 1.59
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement. Int J Cardiol (2006) 1.58